Natalie S Ryan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12025565/publications.pdf

Version: 2024-02-01

72	5,771	136950 32	155660 55
papers	citations	h-index	g-index

83	83	83	9602
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
2	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.8	423
3	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 2016, 79, 929-939.	5.3	381
4	Serum neurofilament light in familial Alzheimer disease. Neurology, 2017, 89, 2167-2175.	1.1	204
5	Alzheimerâ€™s-Causing Mutations Shift AÎ² Length by Destabilizing Î³-Secretase-AÎ²n Interactions. Cell, 2017, 170, 443-456.e14.	28.9	199
6	Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimerâ€™s disease. Brain, 2013, 136, 1399-1414.	7.6	174
7	Clinical phenotype and genetic associations in autosomal dominant familial Alzheimerâ€™s disease: a case series. Lancet Neurology, The, 2016, 15, 1326-1335.	10.2	163
8	Correlating familial Alzheimerâ€™s disease gene mutations with clinical phenotype. Biomarkers in Medicine, 2010, 4, 99-112.	1.4	145
9	Qualitative changes in human Î³-secretase underlie familial Alzheimerâ€™s disease. Journal of Experimental Medicine, 2015, 212, 2003-2013.	8.5	134
10	Diffusion imaging changes in grey matter in Alzheimerâ€™s disease: a potential marker of early neurodegeneration. Alzheimer's Research and Therapy, 2015, 7, 47.	6.2	132
11	Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Human Molecular Genetics, 2015, 24, 5260-5269.	2.9	116
12	An unbiased longitudinal analysis framework for tracking white matter changes using diffusion tensor imaging with application to Alzheimer's disease. NeuroImage, 2013, 72, 153-163.	4.2	111
13	Familial Alzheimerâ€™s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Molecular Psychiatry, 2020, 25, 2919-2931.	7.9	99
14	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
15	The Importance of Group-Wise Registration in Tract Based Spatial Statistics Study of Neurodegeneration: A Simulation Study in Alzheimer's Disease. PLoS ONE, 2012, 7, e45996.	2.5	81
16	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain, 2011, 134, 293-300.	7.6	79
17	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimerâ€™s disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	7.9	76
18	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. Neurobiology of Aging, 2012, 33, 627.e1-627.e12.	3.1	74

#	Article	IF	Citations
19	Abnormalities of fixation, saccade and pursuit in posterior cortical atrophy. Brain, 2015, 138, 1976-1991.	7.6	74
20	The pattern of atrophy in familial Alzheimer disease. Neurology, 2013, 81, 1425-1433.	1.1	67
21	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 19.	6.2	65
22	Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy. Brain, 2019, 142, 2082-2095.	7.6	64
23	Presymptomatic cortical thinning in familial Alzheimer disease. Neurology, 2016, 87, 2050-2057.	1.1	58
24	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. Neurobiology of Aging, 2015, 36, 3140-3151.	3.1	53
25	Familial Alzheimerâ€™s Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis. Cell Reports, 2021, 34, 108615.	6.4	53
26	Alzheimerâ€™s disease in the 100 years since Alzheimerâ€™s death. Brain, 2015, 138, 3816-3821.	7.6	50
27	Imaging endpoints for clinical trials in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 87.	6.2	47
28	Global gray matter changes in posterior cortical atrophy: A serial imaging study. Alzheimer's and Dementia, 2012, 8, 502-512.	0.8	45
29	Extracellular interface between APP and Nicastrin regulates AÎ² length and response to Î³â€secretase modulators. EMBO Journal, 2019, 38, .	7.8	45
30	Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. PLoS ONE, 2012, 7, e43099.	2.5	44
31	AÎ² profiles generated by Alzheimerâ€™s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Molecular Psychiatry, 2022, 27, 2821-2832.	7.9	37
32	Genetic Influences on Atrophy Patterns in Familial Alzheimer's Disease: A Comparison of APP and PSEN1 Mutations. Journal of Alzheimer's Disease, 2013, 35, 199-212.	2.6	36
33	CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease. Neurobiology of Aging, 2020, 91, 5-14.	3.1	30
34	Motor features in posterior cortical atrophy and their imaging correlates. Neurobiology of Aging, 2014, 35, 2845-2857.	3.1	29
35	Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer's disease. Brain Research, 2017, 1655, 23-32.	2.2	29
36	Genetic testing in dementia â€” utility and clinical strategies. Nature Reviews Neurology, 2021, 17, 23-36.	10.1	26

#	Article	IF	Citations
37	Spontaneous ARIA (Amyloid-Related Imaging Abnormalities) and Cerebral Amyloid Angiopathy Related Inflammation in Presenilin 1-Associated Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 1069-1074.	2.6	22
38	Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 112.	6.2	18
39	The age-dependent associations of white matter hyperintensities and neurofilament light in early- and late-stage Alzheimer's disease. Neurobiology of Aging, 2021, 97, 10-17.	3.1	18
40	Plasma amyloid-Î² ratios in autosomal dominant Alzheimerâ€™s disease: the influence of genotype. Brain, 2021, 144, 2964-2970.	7.6	16
41	Cerebral microbleeds in familial Alzheimer's disease. Brain, 2012, 135, e201-e201.	7.6	15
42	Amyloid precursor protein processing in human neurons with an allelic series of the PSEN1 intron 4 deletion mutation and total presenilin-1 knockout. Brain Communications, 2019, 1, fcz024.	3.3	13
43	Disease duration in autosomal dominant familial Alzheimer disease. Neurology: Genetics, 2020, 6, e507.	1.9	13
44	Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimerâ€™s disease: a retrospective cohort analysis. Alzheimer's Research and Therapy, 2020, 12, 126.	6.2	13
45	Variability in the type and layer distribution of cortical AÎ² pathology in familial Alzheimerâ€™s disease. Brain Pathology, 2022, 32, e13009.	4.1	12
46	Defining and describing the pre-dementia stages of familial Alzheimer's disease. Alzheimer's Research and Therapy, 2011, 3, 29.	6.2	11
47	Imaging Biomarkers in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1180, 20-27.	3.8	9
48	Visual short-term memory impairments in presymptomatic familial Alzheimer's disease: A longitudinal observational study. Neuropsychologia, 2021, 162, 108028.	1.6	7
49	Clinical Association of White Matter Hyperintensities Localization in a Mexican Family with Spastic Paraparesis Carrying the PSEN1 A431E Mutation. Journal of Alzheimer's Disease, 2020, 73, 1075-1083.	2.6	6
50	Reply: Implications of presymptomatic change in thalamus and caudate in Alzheimerâ€™s disease. Brain, 2013, 136, e259-e259.	7.6	3
51	O2-04-05: Accelerated Long-Term Forgetting in Presymptomatic Familial Alzheimerâ€™s Disease. , 2016, 12, P231-P231.		2
52	O2â€03â€02: are White Matter Hyperintensities a Core Feature of Alzheimerâ€™s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2016, 12, P226.	0.8	1
53	P1â€524: VISUAL SHORTâ€TERM BINDING DEFICIT IN FAMILIAL ALZHEIMER'S DISEASE: A LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P532.	0.8	1
54	O3â€03â€01: THE SEQUENCE AND TIMING OF PRECLINICAL COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P882.	0.8	1

#	Article	IF	Citations
55	A novel presenilin 1 duplication mutation (Ile168dup) causing Alzheimer's disease associated with myoclonus, seizures and pyramidal features. Neurobiology of Aging, 2021, 103, 137.e1-137.e5.	3.1	1
56	IC-P-193: AUTOMATED SEGMENTATION OF THALAMUS FROM MRI: METHOD VALIDATION AND COMPARISON FOR VOLUMETRIC MEASUREMENT IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P107-P108.		0
57	F5â€02â€02: Longitudinal Atrophy in Autosomal Dominant Ad and Sporadic Ad: Lessons from Dian. Alzheimer's and Dementia, 2016, 12, P368.	0.8	0
58	[P4â€“261]: LONGITUDINAL EVALUATION OF NEUROPSYCHOLOGICAL AND NEUROIMAGING PROGRESSION IN POSTERIOR CORTICAL ATROPHY. Alzheimer's and Dementia, 2017, 13, P1382.	0.8	0
59	[P1â€“219]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2D AND 3D. Alzheimer's and Dementia, 2017, 13, P327.	0.8	0
60	[P1â€“220]: 3D CEREBRAL ORGANOIDS AS IN VITRO MODELS FOR ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P327.	0.8	0
61	[P1â€“025]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2D AND 3D. Alzheimer's and Dementia, 2017, 13, P242.	0.8	0
62	[P1â€“180]: DISTINCT AÎ² PRODUCTION IN STEM CELLâ€DERIVED CORTICAL NEURONS FROM PATIENTS WITH FAD MUTATION. Alzheimer's and Dementia, 2017, 13, P311.	0.8	0
63	[F4â€“01â€“04]: NEUROIMAGING AND HETEROGENEITY IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1211.	0.8	0
64	[O4â€“02â€“04]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER's DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. Alzheimer's and Dementia, 2017, 13, P1230.	0.8	0
65	P1â€188: MODELLING AMYLOID BETA PROFILES IN IPSCâ€DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE. Alzheimer's and Dementia, 2018, 14, P350.	0.8	0
66	O2â€04â€04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P623.	0.8	0
67	P3â€461: THE DISTRIBUTION OF CORTICAL AÎ² AND MICROGLIAL PATHOLOGY IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1295.	0.8	0
68	P3â€261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1174.	0.8	0
69	White matter hyperintensity increases are a feature of familial AD and are associated with increased brain atrophy. Alzheimer's and Dementia, 2020, 16, e038925.	0.8	0
70	Disease duration in autosomal dominant familial Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e039738.	0.8	0
71	Premature neuronal differentiation in familial Alzheimerâ€™s disease human stem cells in vitro and in postmortem brain tissue. Alzheimer's and Dementia, 2020, 16, e039793.	0.8	0
72	Plasma phosphoâ€tau in familial Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042921.	0.8	0